Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies-Reference-Cited by-同舟云学术

Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies

Published:2021-08 Issue:2 Volume:161 Page:715-718.e4
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Wong Serre-Yu^ORCID,Dixon Rebekah,Martinez Pazos Vicky,Gnjatic Sacha,Colombel Jean-Frederic,Cadwell Ken,Gold Stephanie,Helmus Drew,Neil Jessica Anne,Sota Stela,Jang Kyung Ku,Ching Krystal,Venzon Mericien,Yao Xiaomin,Bernard Lucie,Chen Xin,Navalurkar Reema,Mendiolaza Michelle,Reyes-Mercedes Pamela,Nunez Sara,Stanley Stephanie,Jimenez Darwin,Tankelevich Michael,Phillipe Brianne,Ramos Julio,Tuballes Kevin,Barcessat Vanessa,Herrera Natalia,Satsangi Jack,Watanabe Kenji,Vermeire Séverine,Steinwurz Flavio,Silverberg Mark,Rubin David T.,Roda Giulia,Reinisch Walter,Ng Siew Chien,Lindsay James,Halfvarson Jonas,Allez Matthieu,Ahuja Vineet,Abreu Maria

Funder

National Cancer Institute

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference9 articles.

1. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry

2. Effect of IBD medications on COVID-19 outcomes: results from an international registry

3. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting

4. Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19 vaccine updates for people under different conditions;Science China Life Sciences;2024-07-29

2. Humoral and cellular immunogenicity, effectiveness and safety of COVID-19 mRNA vaccination in patients with pediatric rheumatic diseases: A prospective cohort study;Vaccine;2024-02

3. COVID-19 in patients with inflammatory bowel diseases: Characteristics and guidelines;Management, Body Systems, and Case Studies in COVID-19;2024

4. COVID-19 Vaccination and Immunosuppressive Therapy in Immune-Mediated Inflammatory Diseases;Vaccines;2023-12-04

5. COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series;RMD Open;2023-11